Context Therapeutics Inc. (NASDAQ: CNTX)
$2.18
-0.0200 ( -0.91% ) 84.3K
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Market Data
Open
$2.18
Previous close
$2.20
Volume
84.3K
Market cap
$164.25M
Day range
$2.06 - $2.24
52 week range
$0.77 - $2.24
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 26, 2024 |
8-k | 8K-related | 15 | Apr 01, 2024 |
4 | Insider transactions | 1 | Mar 22, 2024 |
4 | Insider transactions | 1 | Mar 22, 2024 |
4 | Insider transactions | 1 | Mar 22, 2024 |
10-k | Annual reports | 69 | Mar 21, 2024 |
8-k | 8K-related | 46 | Mar 21, 2024 |
8-k | 8K-related | 39 | Mar 06, 2024 |
10-q | Quarterly Reports | 52 | Nov 09, 2023 |
8-k | 8K-related | 46 | Oct 31, 2023 |